How much did Faes Farma achieve in EBIT for the current year?
In the current year, Faes Farma has achieved an EBIT of 105.21 M EUR.
Faes Farma EBIT 2024
Faes Farma EBIT
105.21 M EUR
Ticker
FAE.MC
ISIN
ES0134950F36
WKN
A0MKAC
In 2024, Faes Farma's EBIT was 105.21 M EUR, a 2.3% increase from the 102.84 M EUR EBIT recorded in the previous year.
The Faes Farma EBIT history
| YEAR | EBIT (undefined EUR) |
|---|---|
| 2027e | 96.58 |
| 2026e | 110.13 |
| 2025e | 108.59 |
| 2024e | 105.21 |
| 2023 | 102.84 |
| 2022 | 101.92 |
| 2021 | 97.11 |
| 2020 | 92.31 |
| 2019 | 78.98 |
| 2018 | 62.01 |
| 2017 | 49.07 |
| 2016 | 48.04 |
| 2015 | 41.52 |
| 2014 | 36.2 |
| 2013 | 28.6 |
| 2012 | 22.8 |
| 2011 | 16.3 |
| 2010 | 24.7 |
| 2009 | 25.4 |
| 2008 | 26 |
| 2007 | 21.4 |
| 2006 | 23.3 |
| 2005 | 19.9 |
| 2004 | 15.1 |
Faes Farma Revenue, EBIT, Net Income ES0134950F36 · A0MKAC
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Faes Farma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Faes Farma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Faes Farma’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Faes Farma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Faes Farma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Faes Farma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Faes Farma’s growth potential.
Faes Farma Revenue, EBIT and net profit per share
| Date | Faes Farma Revenue | Faes Farma EBIT | Faes Farma Net Income |
|---|---|---|---|
| 2027e | 515.45 M undefined | 96.58 M undefined | 88.59 M undefined |
| 2026e | 513.58 M undefined | 110.13 M undefined | 92.21 M undefined |
| 2025e | 499.02 M undefined | 108.59 M undefined | 93.52 M undefined |
| 2024e | 484.62 M undefined | 105.21 M undefined | 90.38 M undefined |
| 2023 | 451.17 M undefined | 102.84 M undefined | 91.9 M undefined |
| 2022 | 438.75 M undefined | 101.92 M undefined | 89.55 M undefined |
| 2021 | 398.56 M undefined | 97.11 M undefined | 82.39 M undefined |
| 2020 | 380.24 M undefined | 92.31 M undefined | 72.55 M undefined |
| 2019 | 357.4 M undefined | 78.98 M undefined | 63.96 M undefined |
| 2018 | 324.31 M undefined | 62.01 M undefined | 51.59 M undefined |
| 2017 | 274.58 M undefined | 49.07 M undefined | 41.38 M undefined |
| 2016 | 228.64 M undefined | 48.04 M undefined | 36.59 M undefined |
| 2015 | 204.72 M undefined | 41.52 M undefined | 30.36 M undefined |
| 2014 | 191.7 M undefined | 36.2 M undefined | 25.3 M undefined |
| 2013 | 180.4 M undefined | 28.6 M undefined | 22.6 M undefined |
| 2012 | 176.1 M undefined | 22.8 M undefined | 19.5 M undefined |
| 2011 | 195.7 M undefined | 16.3 M undefined | 14.2 M undefined |
| 2010 | 211.4 M undefined | 24.7 M undefined | 20 M undefined |
| 2009 | 199.4 M undefined | 25.4 M undefined | 21.3 M undefined |
| 2008 | 196.9 M undefined | 26 M undefined | 19.6 M undefined |
| 2007 | 203.9 M undefined | 21.4 M undefined | 21.9 M undefined |
| 2006 | 192.5 M undefined | 23.3 M undefined | 22.8 M undefined |
| 2005 | 168.7 M undefined | 19.9 M undefined | 23.3 M undefined |
| 2004 | 165.1 M undefined | 15.1 M undefined | 20.6 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 165.1 M EUR | 15.1 M EUR | 20.6 M EUR |
| 2005 | 168.7 M EUR | 19.9 M EUR | 23.3 M EUR |
| 2006 | 192.5 M EUR | 23.3 M EUR | 22.8 M EUR |
| 2007 | 203.9 M EUR | 21.4 M EUR | 21.9 M EUR |
| 2008 | 196.9 M EUR | 26 M EUR | 19.6 M EUR |
| 2009 | 199.4 M EUR | 25.4 M EUR | 21.3 M EUR |
| 2010 | 211.4 M EUR | 24.7 M EUR | 20 M EUR |
| 2011 | 195.7 M EUR | 16.3 M EUR | 14.2 M EUR |
| 2012 | 176.1 M EUR | 22.8 M EUR | 19.5 M EUR |
| 2013 | 180.4 M EUR | 28.6 M EUR | 22.6 M EUR |
| 2014 | 191.7 M EUR | 36.2 M EUR | 25.3 M EUR |
| 2015 | 204.72 M EUR | 41.52 M EUR | 30.36 M EUR |
| 2016 | 228.64 M EUR | 48.04 M EUR | 36.59 M EUR |
| 2017 | 274.58 M EUR | 49.07 M EUR | 41.38 M EUR |
| 2018 | 324.31 M EUR | 62.01 M EUR | 51.59 M EUR |
| 2019 | 357.4 M EUR | 78.98 M EUR | 63.96 M EUR |
| 2020 | 380.24 M EUR | 92.31 M EUR | 72.55 M EUR |
| 2021 | 398.56 M EUR | 97.11 M EUR | 82.39 M EUR |
| 2022 | 438.75 M EUR | 101.92 M EUR | 89.55 M EUR |
| 2023 | 451.17 M EUR | 102.84 M EUR | 91.9 M EUR |
| 2024e | 484.62 M EUR | 105.21 M EUR | 90.38 M EUR |
| 2025e | 499.02 M EUR | 108.59 M EUR | 93.52 M EUR |
| 2026e | 513.58 M EUR | 110.13 M EUR | 92.21 M EUR |
| 2027e | 515.45 M EUR | 96.58 M EUR | 88.59 M EUR |
Faes Farma stock margins ES0134950F36 · A0MKAC
The Faes Farma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Faes Farma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Faes Farma.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Faes Farma's sales revenue. A higher gross margin percentage indicates that the Faes Farma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Faes Farma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Faes Farma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Faes Farma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Faes Farma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Faes Farma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Faes Farma Margin History
| Faes Farma Gross margin | Faes Farma Profit margin | Faes Farma EBIT margin | Faes Farma Profit margin |
|---|---|---|---|
| 2027e | 65.86 % | 18.74 % | 17.19 % |
| 2026e | 65.86 % | 21.44 % | 17.95 % |
| 2025e | 65.86 % | 21.76 % | 18.74 % |
| 2024e | 65.86 % | 21.71 % | 18.65 % |
| 2023 | 65.86 % | 22.79 % | 20.37 % |
| 2022 | 64.28 % | 23.23 % | 20.41 % |
| 2021 | 63.33 % | 24.37 % | 20.67 % |
| 2020 | 63.08 % | 24.28 % | 19.08 % |
| 2019 | 63.63 % | 22.1 % | 17.9 % |
| 2018 | 62.94 % | 19.12 % | 15.91 % |
| 2017 | 64.88 % | 17.87 % | 15.07 % |
| 2016 | 66.13 % | 21.01 % | 16 % |
| 2015 | 65.34 % | 20.28 % | 14.83 % |
| 2014 | 65.73 % | 18.88 % | 13.2 % |
| 2013 | 63.53 % | 15.85 % | 12.53 % |
| 2012 | 64.22 % | 12.95 % | 11.07 % |
| 2011 | 62.03 % | 8.33 % | 7.26 % |
| 2010 | 60.26 % | 11.68 % | 9.46 % |
| 2009 | 60.88 % | 12.74 % | 10.68 % |
| 2008 | 60.84 % | 13.2 % | 9.95 % |
| 2007 | 66.36 % | 10.5 % | 10.74 % |
| 2006 | 66.65 % | 12.1 % | 11.84 % |
| 2005 | 67.1 % | 11.8 % | 13.81 % |
| 2004 | 66.51 % | 9.15 % | 12.48 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 66.51 % | 9.15 % | 12.48 % |
| 2005 | 67.1 % | 11.8 % | 13.81 % |
| 2006 | 66.65 % | 12.1 % | 11.84 % |
| 2007 | 66.36 % | 10.5 % | 10.74 % |
| 2008 | 60.84 % | 13.2 % | 9.95 % |
| 2009 | 60.88 % | 12.74 % | 10.68 % |
| 2010 | 60.26 % | 11.68 % | 9.46 % |
| 2011 | 62.03 % | 8.33 % | 7.26 % |
| 2012 | 64.22 % | 12.95 % | 11.07 % |
| 2013 | 63.53 % | 15.85 % | 12.53 % |
| 2014 | 65.73 % | 18.88 % | 13.2 % |
| 2015 | 65.34 % | 20.28 % | 14.83 % |
| 2016 | 66.13 % | 21.01 % | 16 % |
| 2017 | 64.88 % | 17.87 % | 15.07 % |
| 2018 | 62.94 % | 19.12 % | 15.91 % |
| 2019 | 63.63 % | 22.1 % | 17.9 % |
| 2020 | 63.08 % | 24.28 % | 19.08 % |
| 2021 | 63.33 % | 24.37 % | 20.67 % |
| 2022 | 64.28 % | 23.23 % | 20.41 % |
| 2023 | 65.86 % | 22.79 % | 20.37 % |
| 2024e | 65.86 % | 21.71 % | 18.65 % |
| 2025e | 65.86 % | 21.76 % | 18.74 % |
| 2026e | 65.86 % | 21.44 % | 17.95 % |
| 2027e | 65.86 % | 18.74 % | 17.19 % |
Faes Farma Aktienanalyse
What does Faes Farma do?
The history of Faes Farma SA dates back to 1933, when the company was founded in Barcelona, Spain. The founders had a vision to develop innovative products that would contribute to improving the health and well-being of people. Over the following decades, the company grew continuously and established itself as one of the leading players in the pharmaceutical industry. The business model of Faes Farma SA is focused on the development and marketing of products for the healthcare industry. The company relies on research and development to develop innovative solutions for various therapeutic areas. Faes Farma SA distributes its products worldwide through a network of partners and distributors, with a focus on Europe and Latin America. Faes Farma SA operates in three different divisions. The first division is pharmaceuticals, where the company offers products for various areas such as respiratory diseases, allergies, pain, and inflammation. An important part of this segment is the product Bilastine, which is used for the treatment of allergies and is considered an alternative to antihistamines. The second division is animal health. Here, Faes Farma SA offers products for the treatment of pets, including preparations against fleas, ticks, and worms. One of the most well-known products in this area is the Stangest brand, which is considered the leading brand for animal health in Spain. The third division of Faes Farma SA is the business of medical devices and diagnostics. Here, the company offers a wide range of products for various medical applications, including devices for monitoring vital signs and diagnostics for infectious diseases. Overall, Faes Farma SA is a company with a diversified product portfolio that is of interest to both end consumers and healthcare professionals and pet owners. The company has continuously developed and invested in research and development in recent years to expand its product offering and provide innovative solutions for various medical needs. Faes Farma SA is a company that stands out for its commitment to the development of innovative products and its dedication to the health and well-being of humans and animals. With a strong focus on research and development and a wide distribution network, the company has solidified its position in the pharmaceutical industry and will continue to play an important role in the market. Faes Farma ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Faes Farma's EBIT
Faes Farma's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Faes Farma's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Faes Farma's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Faes Farma’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Faes Farma stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Faes Farma.
How has the EBIT of Faes Farma developed in recent years?
The EBIT of Faes Farma has increased by 2.305% increased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Faes Farma?
The EBIT of Faes Farma is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Faes Farma pay?
Over the past 12 months, Faes Farma paid a dividend of 0.16 EUR . This corresponds to a dividend yield of about 4.25 %. For the coming 12 months, Faes Farma is expected to pay a dividend of 0.17 EUR.
What is the dividend yield of Faes Farma?
The current dividend yield of Faes Farma is 4.25 %.
When does Faes Farma pay dividends?
Faes Farma pays a quarterly dividend. This is distributed in the months of February, May, February, August.
How secure is the dividend of Faes Farma?
Faes Farma paid dividends every year for the past 24 years.
What is the dividend of Faes Farma?
For the upcoming 12 months, dividends amounting to 0.17 EUR are expected. This corresponds to a dividend yield of 4.62 %.
In which sector is Faes Farma located?
Faes Farma is assigned to the 'Health' sector.
Wann musste ich die Aktien von Faes Farma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Faes Farma from 7/8/2024 amounting to 0.116 EUR, you needed to have the stock in your portfolio before the ex-date on 7/4/2024.
When did Faes Farma pay the last dividend?
The last dividend was paid out on 7/8/2024.
What was the dividend of Faes Farma in the year 2023?
In the year 2023, Faes Farma distributed 0.035 EUR as dividends.
In which currency does Faes Farma pay out the dividend?
The dividends of Faes Farma are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Faes Farma
Our stock analysis for Faes Farma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Faes Farma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
